Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary

Area of Science:

• Endocrinology and Reproductive Medicine
• Nutritional Biochemistry
• Pharmacology

Background:

• Polycystic Ovary Syndrome (PCOS) is frequently managed with inositol-based supplements.
• Current formulations often combine myo-inositol and D-chiro-inositol with other compounds.
• The stereoisomer-specific properties and interactions of inositols are not consistently considered in product design.

Purpose of the Study:

• To critically analyze the composition of commercially available inositol-based products for PCOS treatment.
• To evaluate the therapeutic rationale behind various inositol combination strategies.
• To highlight the importance of stereoisomer-specific dosages and interactions for efficacy.

Main Methods:

• Literature review and critical analysis of existing inositol formulations for PCOS.
• Examination of the pharmacokinetic and pharmacodynamic properties of myo-inositol and D-chiro-inositol.
• Assessment of clinical evidence regarding optimal inositol ratios and potential interactions.

Main Results:

• D-chiro-inositol's efficacy diminishes at higher doses and can negatively impact reproductive outcomes.
• Co-administration of D-chiro-inositol reduces myo-inositol absorption due to transporter competition.
• Certain sugars and inhibitors further decrease myo-inositol intestinal absorption, necessitating higher doses.
• D-chiro-inositol acts as an aromatase inhibitor, potentially increasing androgens and causing adverse effects.

Conclusions:

• Inositol supplements for PCOS require careful formulation, considering stereoisomer-specific effects.
• The optimal ratio for restoring ovulation in PCOS is 40:1 myo-inositol to D-chiro-inositol.
• Many current PCOS inositol treatments lack therapeutic rationale, potentially weakening efficacy with unnecessary or counterproductive ingredients.